Johnson & Johnson and its subsidiaries have approximately 134,000 employees worldwide engaged in the research and development, manufacture, and sale of a broad range of products in the health care field. The company is committed to creating value by developing accessible, high-quality, innovative products and services, ensuring health for people today and for future generations. Management's objectives are centered around blending heart, science, and ingenuity to profoundly change the trajectory of health for humanity, which reflects a strategic response to the demands of rapidly evolving markets. The company leverages extensive resources across the enterprise, enabling innovation and execution with excellence, which ensures a focus on addressing unmet needs of society and investing for an enduring impact. The executive committee oversees and coordinates the activities of the consumer, pharmaceutical, and medical devices business segments, reflecting a systemic perspective on resource allocation and operational flexibility. In 2017, the company invested $10.6 billion in research and development and $35.2 billion on acquisitions, demonstrating a commitment to resilience strategies that create life-enhancing innovations. The company’s diverse workforce is empowered to lead with agility and urgency, which enhances organizational health and adaptability in the face of external pressures and competitive environments. The restructuring actions announced in 2016 are expected to result in annualized pre-tax cost savings, providing the company with added flexibility and resources to fund investment in new growth opportunities and innovative solutions. The company continues to monitor economic conditions and take appropriate actions in response to significant challenges, such as operations in Venezuela, which are considered highly inflationary. The competitive environment necessitates substantial investments in continuing research and the development of new and innovative products, which are critical for maintaining firm performance and competitive advantage. The company’s strategic initiatives include enhancing customer demand through significant expenditures for advertising and promotion, reflecting an understanding of the complexities of the market landscape. The company’s ability to absorb strain and preserve functioning despite adversity is evident in its operational management and strategic adaptation processes. The company’s commitment to resilience is further illustrated by its focus on collaboration networks and inter-organizational collaboration, which enhance its capacity to respond effectively to environmental disruptions. The ongoing evaluation of potential strategic options for business segments, such as the decision to exit the animas insulin pump business, underscores the company's proactive measures in crisis management and operational continuity. The company’s financial resources and access to liquidity through various channels ensure sufficient resources to fund operating needs, reflecting a robust organizational capability to navigate uncertainties and maintain performance under pressure.